Baudax Bio, Inc. is a pharmaceutical enterprise dedicated to creating and marketing therapeutic solutions for inpatient and urgent care environments. Their flagship commercial offering is ANJESO, an injectable meloxicam formulation designed to alleviate moderate to severe pain, which can be administered independently or in conjunction with non-NSAID pain medications. The company's research and development portfolio features several candidates: BX1000, an intermediate-acting neuromuscular blocker currently in Phase II trials; BX2000, an ultra-short-acting variant of the same class, undergoing Phase I investigation; BX3000, an agent intended to reverse neuromuscular blockade; and Dex-IN, a unique intranasal delivery system for dexmedetomidine. Founded in 2019, the firm operates from its base in Malvern, Pennsylvania.